What question did this study set out to answer?

To establish evidence-based, regionally adapted recommendations for the diagnosis, staging, risk stratification, treatment, and follow-up of adult patients with peripheral T-cell lymphoma not otherwise specified in Latin America.

September 1, 2026JCO Global OncologyOpen Access

Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified

View Full Paper

Ask AI

Bookmark

Authors

HIHenry IdroboTechnological University of Pereira JGJuan Esteban García-RobledoInstituto de Cancerología Las Américas JOJuan Alejandro OspinaInstituto Nacional de Cancerología

Discussion

Member takes

Implication

Expert consensus reveals clinical recommendations for peripheral T-cell lymphoma in Latin America, highlighting standardized staging and resource-adapted treatment protocols.

Key Points

To establish evidence-based, regionally adapted recommendations for the diagnosis, staging, risk stratification, treatment, and follow-up of adult patients with peripheral T-cell lymphoma not otherwise specified in Latin America.
Multidisciplinary panel of hematologists and oncologists from multiple Latin American countries, members of the Grupo de Estudio Latinoamericano de Linfoproliferativos, conducted a modified Delphi process between February and July 2025.
An 11-item questionnaire evaluated diagnostic workup, staging, risk scores, therapy lines, transplantation, and supportive care using the RAND/UCLA appropriateness method across two anonymous voting rounds with consensus defined as ≥80% agreement on a 5-point Likert scale.
Staging and diagnostic recommendations mandate PET/CT with total metabolic tumor volume, bone marrow biopsy, standardized immunohistochemistry or flow cytometry, and the Prognostic Index for PTCL-U for risk stratification.
First-line therapeutic guidance advises cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) for fit patients aged ≤60 years with planned consolidation via autologous stem-cell transplantation, CHOP-21 for other patients, and brentuximab vedotin plus CHP for CD30-positive cases (≥10% expression).
Response monitoring requires interim and post-treatment PET/CT, autologous stem-cell transplantation consolidation in first complete remission, and early allogeneic stem-cell transplantation referral for relapsed or refractory disease.

Cite This Study

Idrobo et al. (2026) studied this question.

synapsesocial.com/papers/6aa844922a15e1be46003473 https://doi.org/10.1200/go-26-00265

View Full Paper

Ask AI

Bookmark

Implication

Expert consensus reveals clinical recommendations for peripheral T-cell lymphoma in Latin America, highlighting standardized staging and resource-adapted treatment protocols.

Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified

Discussion

Member takes

Implication

Key Points

Cite This Study

Latin American Consensus for the Diagnosis, Staging, and Treatment of Peripheral T-Cell Lymphoma Not Otherwise Specified

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider